ClinicalTrials.gg
RecruitingNCT07566377Updated May 14, 2026

Cord Blood Transplantation in Children and Young Adults With Blood Cancer

A Phase 2 interventional study of Cord Blood Units and Total Body Irradiation in Acute Myelogenous Leukemia, Acute Lymphoblastic Leukemia and Myelodysplastic Syndromes, sponsored by Memorial Sloan Kettering Cancer Center. Recruiting at 1 site in United States. Open to participants aged Up to 26 Years. Per ClinicalTrials.gov, last updated 2026-05-14.

Sponsored by Memorial Sloan Kettering Cancer Center · Phase 2, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Apr 2026; still recruiting 6 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
71
Allocation
Non-randomized
Ages
Up to 26 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 155 studies testing cyclophosphamide in Leukemia, Myeloid, Acute — 22 open to participants now, 34 under way, 1 of them phase 3. Cyclophosphamide · Leukemia, Myeloid, Acute.

Planned enrollment
42nd of 148
71 · median 39
Started
2026
with 5 others
Phase 2
89 of 155
12 open now
Primary completion
2030-04
later than 29 of 33 live
Registered
152nd of 155
by date
Lead sponsor
7 of 155
Memorial Sloan Kettering Cancer Center

Among the 155 studies testing cyclophosphamide in Leukemia, Myeloid, Acute, this one is the 42nd largest by planned enrollment of the 148 interventional ones that give a count, is one of 6 that started in 2026, is one of 89 in phase 2, reaches primary completion later than 29 of the 33 other live ones, and was the 152nd registered.

Leukemia, Myeloid, Acute

3,672 studies on the registry are indexed under Leukemia, Myeloid, Acute; 812 are open to participants now.

Browse Leukemia, Myeloid, Acute studies →

Open to participants now

22 of the 155 studies testing cyclophosphamide in Leukemia, Myeloid, Acute are open now, in 4 countries. Recruiting first, the newest first:

16 more — sign in →

By country, each count listing its studies:

All 22 open studies →

About cyclophosphamide

Cyclophosphamide: first FDA approval 1959 (CYTOXAN). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 617 Leukemia, Myeloid, Acute studies recruiting now, 359 (58%) set no upper age limit and 219 (35%) stop at 75 or younger; 144 take children under 18; 29 take healthy volunteers.

This study: Up to 26 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 155 studies testing cyclophosphamide in Leukemia, Myeloid, Acute, or all of them as a file.
02

Study summary

The purpose of this study is to find out whether Cord Blood Transplantation/CBT as the first or second transplant is an effective treatment for children and young adults with blood cancer.

03

Conditions studied

  • Acute Myelogenous Leukemia
  • Acute Lymphoblastic Leukemia
  • Myelodysplastic Syndromes
  • Non-hodgkin Lymphoma
  • Hodgkin Lymphoma
  • Leukemia
  • Lymphoma
  • Graft-versus-host Disease

Keywords

  • Cord blood transplants
  • Graft-versus-host Disease
  • Lymphoma
  • Leukemia
  • Hodgkin Lymphoma
  • Non-hodgkin Lymphoma
  • Myelodysplastic Syndromes
  • Acute Lymphoblastic Leukemia
  • Acute Myelogenous Leukemia
  • Memorial Sloan Kettering Cancer Center
  • 26-168
04

Who can participate

Ages eligible
Up to 26 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Inclusion Criteria:

A patient cannot be considered eligible for this study unless ALL of the following conditions are met.

° Disease type

Cohort 1, High Risk Disease: Patients with age ≤ 26 years at the time of with no available and suitably matched related or unrelated donor within 4 weeks, with one of the following diagnoses:

I. Acute myelogenous leukemia (AML):

  • Complete first remission (CR1) with blast count \< 5% by bone marrow morphology at high risk for relapse such as any of the following:

    • Known prior diagnosis of myelodysplasia (MDS)
    • High risk cytogenetics (e.g., those associated with MDS, abnormalities of 5, 7, 8, complex karyotype) and/or high-risk molecular abnormalities (e.g., TP53)
    • Requirement for 2 or more inductions to achieve CR1
    • Therapy-related AML (t-AML) or therapy-related myeloid neoplasm (t-MN) (including after therapy for other , and/or gene therapy or cell therapy)
    • Presence of Minimal/Measurable Residual Disease (MRD+) by cytogenetics, flow cytometry or molecular methods (at End of Induction or End of Consolidation)
    • Other high-risk features not defined above.
  • Complete second remission (CR2) or subsequent remission, with blast count \< 5% by bone marrow morphology
  • Presence of MRD by multiparameter flow cytometry at pre-transplant evaluation is acceptable.

II. Acute lymphoblastic leukemia (ALL):

  • Complete first remission (CR1) with MRD negative status by multicolor flow cytometry, at high risk for relapse such as any of the following:

    • Presence of any high risk cytogenetic abnormalities such as t(9;22), t(1;19), t(4;11) or other, KMT2A (11q23) or other high risk molecular abnormality
    • Failure to achieve complete remission (CR) after four weeks of induction therapy (transplant to follow antibody therapy and/or CAR T cells)
    • Persistence or recurrence of MRD on therapy (Transplant to follow antibody therapy and/or CAR T cells)
    • T-ALL in CR even with presence of MRD
    • Other high-risk features not defined above
  • Complete second remission (CR2) or subsequent remission with MRD negative status by multiparameter flow cytometry.

    • Relapse in less than 36 months from CR1
    • Relapse for T-ALL
  • Patients after antibody therapy (e.g., blinatumomab, inotuzumab, other) and/or CAR-T cell therapy that resulted in MRD negative status by multiparameter flow cytometry.

III. Other acute leukemias:

  • Leukemias of ambiguous lineage or of other types with \< 5% blasts by bone marrow morphology.
  • Patients with persistent/ disease with cytogenetic, flow cytometric or molecular aberrations in \< 5% of cells.
  • Chronic myelogenous leukemia: Patients with history of blast crisis or accelerated phase.
  • Any leukemia that developed after gene therapy or cell therapy

IV. Myelodysplastic Syndrome (MDS):

  • Any IPSS risk category with life-threatening cytopenia(s).
  • Any IPSS risk category with high risk cytogenetic/molecular findings (5, 7, 8, complex karyotype, or TP53)

V. Non-Hodgkin lymphoma (NHL) or Hodgkin lymphoma (HL) at high risk of relapse or progression if not in remission:

  • Patients with aggressive histology (such as, but not limited to, diffuse large B-cell NHL, mantle cell NHL, and T-cell NHL) in CR.
  • Patients with indolent B cell NHL (such as, but not limited to, follicular, small cell or marginal zone NHL) will have 2nd or subsequent progression with stable disease/ CR/ PR with no single lesion equal to or more than 5 cm.
  • Patients with HL without progression of disease (POD) after salvage chemotherapy with no single lesion ≥5 cm.

Cohort 2: Very High-Risk disease:

  1. Patients in CR (bone marrow blasts \<5% by morphology) who had prior transplant and disease recurrence. The second transplant will take place at least 4 months after the first.

    • Acute myelogenous leukemia (AML) or Myelodysplastic Syndrome (MDS): Relapse after previous transplant, in CR after induction therapy. MRD positive status by multi-parameter flow cytometry is accepted.
    • Acute lymphoblastic leukemia (ALL): Relapse after previous transplant, in CR after induction therapy and/or antibody therapy/CAR T cells. MRD positive status after targeted therapy, as evaluated by multi-parameter flow cytometry is accepted.
    • Other: patients with leukemia or lymphoma, who, in the opinion of their physician, are not likely to have reduction in disease burden with further chemotherapy.
  2. Patients with relapsed/refractory disease at either first or second allogeneic transplant, with up to 30% bone marrow blasts by multiparameter flow cytometry or morphology. ° Relapse after previous transplant with \< 30% blasts by bone marrow morphology, or with cytogenetic, flow cytometric, or molecular abnormalities in \< 30% of bone marrow cells, after induction therapy.

    ° Primary refractory or relapsed AML with \< 30% blasts by bone marrow morphology or with cytogenetic, flow cytometric, or molecular abnormalities in \< 30% of bone marrow cells.

    ° Age 0-26 years at the time of informed consent

    ° Performance: (≥16 years) or Lansky score (\<16 years) of ≥70% (see Appendix A).

    ° Not Pregnant and Not Nursing

    ° Required Organ Function

    • ≤ 1.5 mg/dL (unless benign congenital hyperbilirubinemia).
    • ≤ 3 x .
    • Pulmonary function (FVC, and DLCO corrected for ) ≥ 50% predicted.

      • In young children unable to perform pulmonary function testing: pulse oximetry >92% in room air, and a normal CT of the chest (if CT is not normal, the child needs to be evaluated and cleared by pediatric pulmonary physician).
    • > 50%.
    • Age-adjusted Hematopoietic Cell Transplantation-Comorbidity Index (aaHCT-CI) ≤ 7.
    • Female patients of must have a negative serum pregnancy test within 7 days of enrolment and must be willing to use an effective method while enrolled in the study.
    • Renal: Serum creatinine (SCr) ≤ 1.5 x normal for age. If SCr is outside the normal range, then > 50 mL/min (calculated or estimated) or estimated (mL/min/1.73m2) >30% of predicted normal for age.

    Normal GFR by Age : Mean GFR +- SD (mL/min/1.73m\^2) 1 week : 40.6 + / - 14.8 2-8 weeks : 65.8 + / - 24.8 >8 weeks : 95.7 + / - 21.7 2-12 years : 133.0 + / - 27.0 13-21 years (males) : 140.0 + / - 30.0 13-21 years (females) : 126.0 + / - 22.0

    GFR, glomerular filtration rate; SD, standard deviation; Greater than 2 years old: Normal GFR is 100 mL/ min; Infants: GFR must be corrected for body surface area.

    Exclusion Criteria:

    Exclusion criteria for both cohorts:

    ° Inadequate performance status/ organ function.

    ° Active CNS leukemic involvement.

    • Chloroma >2 cm.
    • Active and uncontrolled infection (bacterial/fungal/viral) at time of transplant.
    • infection.
    • Seropositivity for HTLV-1.
    • Pregnancy or breast feeding.
    • Patient or guardian unable to give informed consent or unable to comply with the treatment protocol including appropriate supportive care, long-term follow-up, and research tests.
    • Any abnormal condition or lab result that is considered by the PI capable or altering patient's condition or study outcome.

    Cohort 2 Very High-Risk Disease (additional to above):

    ° Allogeneic HCT in the preceding 4 months.

    Note (1): Prior /blockade in the last 12 months: eligibility to be discussed with study PI.

    Note (2): For patients with known and/or infection :

    • For patients with evidence of chronic hepatitis B virus (HBV) infection, the HBV viral load must be undetectable on suppressive therapy, if indicated.
    • Patients with a history of hepatitis C virus (HCV) infection must have been treated and cured. For patients with HCV infection who are currently on treatment, they are eligible if they have an undetectable HCV viral load.
Terms in these criteria, in plain language(19)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Karnofsky performance status (KPS)

A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.

Studies often ask for 60 or 70 and above. Your doctor gives the score.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
71 participants (estimated)

Study arms

  • Experimental
    Cohort 1: Patients with High-Risk Disease

    Participants in complete remission (CR; bone marrow blasts \<5% by morphology) with no prior allogeneic transplant, who require allogeneic transplantation and do not have human leukocyte antigen (HLA)-matched related or unrelated donors readily available within 4 weeks. For participants with AML/MDS, MRD (Measurable/Minimal Residual Disease) positive status at the time of transplant is accepted (evaluated by multiparameter flow cytometry); participants with ALL need to be in MRD negative status (evaluated by multiparameter flow cytometry).

    Biological: Cord Blood Units · Radiation: Total Body Irradiation · Drug: Cyclophosphamide · Drug: Fludarabine · Drug: Clofarabine · Drug: Busulfan · Drug: Thiotepa · Drug: Tacrolimus · Drug: Mycophenolate Mofetil · Drug: Cyclosporine

  • Experimental
    Cohort 2: Patients with Very High-Risk Disease

    1. Participants in CR (bone marrow blasts \<5% by morphology) who had prior allogeneic transplant and disease recurrence. 1. Participants with AML/MDS: MRD positive status at the time of transplant is accepted (evaluated by multiparameter flow cytometry) 2. Participants with ALL: MRD positive status at the time of transplant is accepted (evaluated by multiparameter flow cytometry). 3. The second transplant will take place at least 4 months after the first. 2. Participants with relapsed/refractory disease at first or second allogeneic transplant, with up to 30% bone marrow blasts by multiparameter flow cytometry or morphology.

    Biological: Cord Blood Units · Radiation: Total Body Irradiation · Drug: Cyclophosphamide · Drug: Fludarabine · Drug: Clofarabine · Drug: Busulfan · Drug: Thiotepa · Drug: Tacrolimus · Drug: Mycophenolate Mofetil · Drug: Cyclosporine

Interventions

  • BiologicalCord Blood Units

    Cord Blood \[(HPC(CB)\] products are minimally manipulated unrelated allogeneic cord blood units that have been collected, processed and stored in public Cord Blood banks

  • RadiationTotal Body Irradiation

    Hyper-fractionated TBI is administered by a linear accelerator at a dose rate of \<20 cGy/minute. Treatment planning begins with simulation.

    Also known as: TBI

  • Cyclophosphamide is an alkylating agent that prevents cell division by cross-linking DNA strands and decreasing DNA synthesis.

    Also known as: Cytoxan, Neosar

  • Fludarabine phosphate is rapidly dephosphorylated to 2- fluoro-ara- A and then phosphorylated intracellularly by deoxycytidine kinase to the active triphosphate, 2- fluoro-ara-ATP

    Also known as: Fludara

  • Clofarabine, a purine (deoxyadenosine) nucleoside analog, is metabolized to clofarabine 5'-triphosphate.

    Also known as: Clolar

  • Busulfan is a bifunctional alkylating agent known chemically as 1,4- butanediol, dimethanesulfonate.

    Also known as: Busulfex

  • Thiotepa is an alkylating agent which produces cross-linking of DNA strands leading to inhibition of DNA, RNA, and protein synthesis; thiotepa is cell-cycle independent.

    Also known as: Thioplex

  • Tacrolimus inhibits T-lymphocyte activation

  • DrugMycophenolic AcidStudies of Mycophenolic AcidMycophenolic Acid pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Mycophenolate exhibits a cytostatic effect on T and B lymphocytes.

  • Cyclosporine is a calcineurin inhibitor that inhibits production and release of interleukin II and inhibits interleukin II-induced activation of resting T-lymphocytes.

06

What researchers measure

Primary outcomes

  1. Disease-free Survival (DFS)

    Disease-free Survival (DFS) at 1 year after CBT

    Time frame: 1 year

07

Study locations

1 of 1 sites recruiting
  • Memorial Sloan Kettering Cancer Center (All Protocol Activities)
    New York, New York 10065, United States
    Recruiting
    • Andromachi Scaradavou, MD · Contact1-833-MSK-KIDS
08

References and documents

Individual participant data

Plan to share: Yes — Memorial Sloan Kettering Cancer Center supports the international committee of medical journal editors (ICMJE) and the ethical obligation of responsible sharing of data from clinical trials. The protocol summary, a statistical summary, and informed consent form will be made available on clinicaltrials.gov when required as a condition of Federal awards, other agreements supporting the research and/or as otherwise required. Requests for deidentified individual participant data can be made following one year after publication and for up to 36 months later. Deidentified individual participant data reported in the manuscript will be shared under the terms of a Data Use Agreement and may only be used for approved proposals. Requests may be made to: crdatashare@mskcc.org.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2026 (actual). Primary completion is estimated for Apr 2030, 48 months after the start.

Of 385 non-industry phase 2 interventional studies under Leukemia, Myeloid, Acute, half reached primary completion within 66 months of starting (the median), counting those still running; a quarter within 40 and three quarters within 107. This study's planned 48 months is below that.

Counting every sponsor, half of 442 studies reached it within 60 months; a quarter within 38 and three quarters within 104.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 29, 2026
First posted
May 5, 2026
StartActual
Apr 28, 2026
Primary completionEst.
Apr 28, 2030
CompletionEst.
Apr 28, 2030
Last update
May 14, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 14, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07566377
Responsible party
Sponsor
First posted
May 5, 2026
Start date
Apr 28, 2026
Primary completion
Apr 28, 2030 (estimated)
Completion
Apr 28, 2030 (estimated)
Last update
May 14, 2026

Study contacts

Andromachi Scaradavou, MD
Contact
ScaradaA@mskcc.org
833-MSK-KIDS
Jaap Jan Boelens, MD, PhD
Contact
boelensj@mskcc.org
833-MSK-KIDS
Andromachi Scaradavou, MD
principal investigator · Memorial Sloan Kettering Cancer Center

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Cyclophosphamide · Fludarabine · Clofarabine · Busulfan · Thiotepa · Tacrolimus · Mycophenolic Acid · Cyclosporine

Start the discussion